296 related articles for article (PubMed ID: 32161444)
1. The Advantages of Levodopa-Carbidopa Intestinal Gel for Patients with Advanced Parkinson's Disease: A Systematic Review.
Zhang XR; Jiang ZY; Zhang ZR; Chen HJ; Wu K; He JC; Xie CL
Drug Des Devel Ther; 2020; 14():845-854. PubMed ID: 32161444
[TBL] [Abstract][Full Text] [Related]
2. The Long-Term Impact of Levodopa/Carbidopa Intestinal Gel on 'Off'-time in Patients with Advanced Parkinson's Disease: A Systematic Review.
Antonini A; Odin P; Pahwa R; Aldred J; Alobaidi A; Jalundhwala YJ; Kukreja P; Bergmann L; Inguva S; Bao Y; Chaudhuri KR
Adv Ther; 2021 Jun; 38(6):2854-2890. PubMed ID: 34018146
[TBL] [Abstract][Full Text] [Related]
3. Current Practices for Outpatient Initiation of Levodopa-Carbidopa Intestinal Gel for Management of Advanced Parkinson's Disease in the United States.
Amjad F; Bhatti D; Davis TL; Oguh O; Pahwa R; Kukreja P; Zamudio J; Metman LV
Adv Ther; 2019 Sep; 36(9):2233-2246. PubMed ID: 31278691
[TBL] [Abstract][Full Text] [Related]
4. Levodopa-Carbidopa Intestinal Gel in Patients with Parkinson's Disease: A Systematic Review.
Wirdefeldt K; Odin P; Nyholm D
CNS Drugs; 2016 May; 30(5):381-404. PubMed ID: 27138916
[TBL] [Abstract][Full Text] [Related]
5. The cost-effectiveness of levodopa/carbidopa intestinal gel compared to standard care in advanced Parkinson's disease.
Lowin J; Sail K; Baj R; Jalundhwala YJ; Marshall TS; Konwea H; Chaudhuri KR
J Med Econ; 2017 Nov; 20(11):1207-1215. PubMed ID: 28895769
[TBL] [Abstract][Full Text] [Related]
6. Jejunal Infusion of levodopa-carbidopa intestinal gel versus oral administration of levodopa-carbidopa tablets in japanese subjects with advanced Parkinson's disease: pharmacokinetics and pilot efficacy and safety.
Othman AA; Chatamra K; Mohamed ME; Dutta S; Benesh J; Yanagawa M; Nagai M
Clin Pharmacokinet; 2015 Sep; 54(9):975-84. PubMed ID: 25875940
[TBL] [Abstract][Full Text] [Related]
7. Levodopa/carbidopa intestinal gel infusion in advanced Parkinson's disease: a 7-year experience.
Zibetti M; Merola A; Artusi CA; Rizzi L; Angrisano S; Reggio D; De Angelis C; Rizzone M; Lopiano L
Eur J Neurol; 2014 Feb; 21(2):312-8. PubMed ID: 24313838
[TBL] [Abstract][Full Text] [Related]
8. Levodopa-carbidopa intestinal gel (LCIG) treatment in routine care of patients with advanced Parkinson's disease: An open-label prospective observational study of effectiveness, tolerability and healthcare costs.
Pålhagen SE; Sydow O; Johansson A; Nyholm D; Holmberg B; Widner H; Dizdar N; Linder J; Hauge T; Jansson R; Bergmann L; Kjellander S; Marshall TS
Parkinsonism Relat Disord; 2016 Aug; 29():17-23. PubMed ID: 27318707
[TBL] [Abstract][Full Text] [Related]
9. Problems related to levodopa-carbidopa intestinal gel treatment in advanced Parkinson's disease.
Udd M; Lyytinen J; Eerola-Rautio J; Kenttämies A; Lindström O; Kylänpää L; Pekkonen E
Brain Behav; 2017 Jul; 7(7):e00737. PubMed ID: 28729942
[TBL] [Abstract][Full Text] [Related]
10. Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: final 12-month, open-label results.
Fernandez HH; Standaert DG; Hauser RA; Lang AE; Fung VS; Klostermann F; Lew MF; Odin P; Steiger M; Yakupov EZ; Chouinard S; Suchowersky O; Dubow J; Hall CM; Chatamra K; Robieson WZ; Benesh JA; Espay AJ
Mov Disord; 2015 Apr; 30(4):500-9. PubMed ID: 25545465
[TBL] [Abstract][Full Text] [Related]
11. Levodopa-Carbidopa Intestinal Gel Monotherapy: GLORIA Registry Demographics, Efficacy, and Safety.
Poewe W; Bergmann L; Kukreja P; Robieson WZ; Antonini A
J Parkinsons Dis; 2019; 9(3):531-541. PubMed ID: 31282424
[TBL] [Abstract][Full Text] [Related]
12. Burden of non-motor symptoms in Parkinson's disease patients predicts improvement in quality of life during treatment with levodopa-carbidopa intestinal gel.
Ray Chaudhuri K; Antonini A; Robieson WZ; Sanchez-Soliño O; Bergmann L; Poewe W;
Eur J Neurol; 2019 Apr; 26(4):581-e43. PubMed ID: 30353942
[TBL] [Abstract][Full Text] [Related]
13. Levodopa/carbidopa intestinal gel can improve both motor and non-motor experiences of daily living in Parkinson's disease: An open-label study.
Juhász A; Aschermann Z; Ács P; Janszky J; Kovács M; Makkos A; Harmat M; Tényi D; Karádi K; Komoly S; Takáts A; Tóth A; Nagy H; Klivényi P; Dibó G; Dézsi L; Zádori D; Annus Á; Vécsei L; Varannai L; Kovács N
Parkinsonism Relat Disord; 2017 Apr; 37():79-86. PubMed ID: 28185758
[TBL] [Abstract][Full Text] [Related]
14. Long-term safety and maintenance of efficacy of levodopa-carbidopa intestinal gel: an open-label extension of the double-blind pivotal study in advanced Parkinson's disease patients.
Slevin JT; Fernandez HH; Zadikoff C; Hall C; Eaton S; Dubow J; Chatamra K; Benesh J
J Parkinsons Dis; 2015; 5(1):165-74. PubMed ID: 25588353
[TBL] [Abstract][Full Text] [Related]
15. An Artificial Neural Network Predicts Gender Differences of Motor and Non-Motor Symptoms of Patients with Advanced Parkinson's Disease under Levodopa-Carbidopa Intestinal Gel.
Bougea A; Derikvand T; Efthimiopoulou E
Medicina (Kaunas); 2024 May; 60(6):. PubMed ID: 38929490
[No Abstract] [Full Text] [Related]
16. Comprehensive assessment of levodopa-carbidopa intestinal gel for Turkish advanced Parkinson’s disease patients.
Sücüllü Karadağ Y; Saltoğlu T; Erdoğan Küçükdağli F; Öztürk Ö; Köseoğlu HT; Altiparmak E
Turk J Med Sci; 2021 Feb; 51(1):84-89. PubMed ID: 32718129
[TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetics of levodopa in subjects with advanced Parkinson's disease: levodopa-carbidopa intestinal gel infusion vs. oral tablets.
Othman AA; Dutta S
Br J Clin Pharmacol; 2014 Jul; 78(1):94-105. PubMed ID: 24433449
[TBL] [Abstract][Full Text] [Related]
18. The effect of levodopa-carbidopa intestinal gel infusion long-term therapy on motor complications in advanced Parkinson's disease: a multicenter Romanian experience.
Băjenaru O; Ene A; Popescu BO; Szász JA; Sabău M; Mureşan DF; Perju-Dumbrava L; Popescu CD; Constantinescu A; Buraga I; Simu M
J Neural Transm (Vienna); 2016 Apr; 123(4):407-14. PubMed ID: 26699635
[TBL] [Abstract][Full Text] [Related]
19. Cost-utility analysis of levodopa carbidopa intestinal gel (Duodopa) in the treatment of advanced Parkinson's disease in patients in Scotland and Wales.
Kalabina S; Belsey J; Pivonka D; Mohamed B; Thomas C; Paterson B
J Med Econ; 2019 Mar; 22(3):215-225. PubMed ID: 30484353
[TBL] [Abstract][Full Text] [Related]
20. Motor and non-motor outcomes in patients with advanced Parkinson's disease treated with levodopa/carbidopa intestinal gel: final results of the GREENFIELD observational study.
Lopiano L; Modugno N; Marano P; Sensi M; Meco G; Solla P; Gusmaroli G; Tamma F; Mancini F; Quatrale R; Zangaglia R; Bentivoglio A; Eleopra R; Gualberti G; Melzi G; Antonini A
J Neurol; 2019 Sep; 266(9):2164-2176. PubMed ID: 31134377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
